Literature DB >> 20936866

Subtype selectivity of dopamine receptor ligands: insights from structure and ligand-based methods.

Qi Wang1, Robert H Mach, Robert R Luedtke, David E Reichert.   

Abstract

Subtype selective dopamine receptor ligands have long been sought after as therapeutic and/or imaging agents for the treatment and monitoring of neurologic disorders. We report herein on a combined structure- and ligand-based approach to explore the molecular mechanism of the subtype selectivity for a large class of D₂-like dopamine receptor ligands (163 ligands in total). Homology models were built for both human D(₂L) and D₃ receptors in complex with haloperidol. Other ligands, which included multiple examples of substituted phenylpiperazines, were aligned against the binding conformations of haloperidol, and three-dimensional quantitative structure activity relationship (3D-QSAR) analyses were carried out. The receptor models show that although D₂ and D₃ share highly similar folds and 3D conformations, the slight sequence differences at their extracellular loop regions result in the binding cavity in D₂ being comparably shallower than in D₃, which may explain why some larger ligands bind with greater affinity at D₃ compared to D₂ receptors. The QSAR models show excellent correlation and high predictive power even when evaluated by the most stringent criteria. They confirm that the origins of subtype selectivity for the ligands arise primarily due to differences in the contours of the two binding sites. The predictive models suggest that while both steric and electrostatic interactions contribute to the compounds' binding affinity, the major contribution arises from hydrophobic interactions, with hydrogen bonding conferring binding specificity. The current work provides clues for the development of more subtype selective dopamine receptor ligands. Furthermore, it demonstrates the possibility of being able to apply similar modeling methods to other subtypes or classes of receptors to study GPCR receptor-ligand interactions at a molecular level.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20936866      PMCID: PMC4022043          DOI: 10.1021/ci1002747

Source DB:  PubMed          Journal:  J Chem Inf Model        ISSN: 1549-9596            Impact factor:   4.956


  50 in total

1.  Interactive SAR studies: rational discovery of super-potent and highly selective dopamine D3 receptor antagonists and partial agonists.

Authors:  Laura Bettinetti; Karin Schlotter; Harald Hübner; Peter Gmeiner
Journal:  J Med Chem       Date:  2002-10-10       Impact factor: 7.446

2.  Rational selection of training and test sets for the development of validated QSAR models.

Authors:  Alexander Golbraikh; Min Shen; Zhiyan Xiao; Yun-De Xiao; Kuo-Hsiung Lee; Alexander Tropsha
Journal:  J Comput Aided Mol Des       Date:  2003 Feb-Apr       Impact factor: 3.686

3.  The retinal conformation and its environment in rhodopsin in light of a new 2.2 A crystal structure.

Authors:  Tetsuji Okada; Minoru Sugihara; Ana-Nicoleta Bondar; Marcus Elstner; Peter Entel; Volker Buss
Journal:  J Mol Biol       Date:  2004-09-10       Impact factor: 5.469

Review 4.  Dopamine D3 receptor ligands: recent advances in the control of subtype selectivity and intrinsic activity.

Authors:  Frank Boeckler; Peter Gmeiner
Journal:  Biochim Biophys Acta       Date:  2006-12-15

5.  Multi-receptor binding profile of clozapine and olanzapine: a structural study based on the new beta2 adrenergic receptor template.

Authors:  Jana Selent; Laura López; Ferran Sanz; Manuel Pastor
Journal:  ChemMedChem       Date:  2008-08       Impact factor: 3.466

6.  Chirospecific and subtype selective dopamine receptor binding of heterocyclic methoxynaphthamide analogs.

Authors:  Laura Bettinetti; Harald Hübner; Peter Gmeiner
Journal:  Arch Pharm (Weinheim)       Date:  2005-06       Impact factor: 3.751

7.  QSAR modeling on dopamine D2 receptor binding affinity of 6-methoxy benzamides.

Authors:  Soma Samanta; Bikash Debnath; Shovanlal Gayen; Balaram Ghosh; Anindya Basu; Kolluru Srikanth; Tarun Jha
Journal:  Farmaco       Date:  2005-08-01

8.  Structural determinants of pharmacological specificity between D(1) and D(2) dopamine receptors.

Authors:  Hongxiang Lan; Curtiss J Durand; Martha M Teeter; Kim A Neve
Journal:  Mol Pharmacol       Date:  2005-10-19       Impact factor: 4.436

9.  Structure-activity relationships for a novel series of dopamine D2-like receptor ligands based on N-substituted 3-aryl-8-azabicyclo[3.2.1]octan-3-ol.

Authors:  Noel M Paul; Michelle Taylor; Rakesh Kumar; Jeffrey R Deschamps; Robert R Luedtke; Amy Hauck Newman
Journal:  J Med Chem       Date:  2008-09-06       Impact factor: 7.446

10.  N-(4-(4-(2,3-dichloro- or 2-methoxyphenyl)piperazin-1-yl)butyl)heterobiarylcarboxamides with functionalized linking chains as high affinity and enantioselective D3 receptor antagonists.

Authors:  Amy Hauck Newman; Peter Grundt; George Cyriac; Jeffrey R Deschamps; Michelle Taylor; Rakesh Kumar; David Ho; Robert R Luedtke
Journal:  J Med Chem       Date:  2009-04-23       Impact factor: 7.446

View more
  28 in total

Review 1.  From laptop to benchtop to bedside: structure-based drug design on protein targets.

Authors:  Lu Chen; John K Morrow; Hoang T Tran; Sharangdhar S Phatak; Lei Du-Cuny; Shuxing Zhang
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

2.  Comparison of the binding and functional properties of two structurally different D2 dopamine receptor subtype selective compounds.

Authors:  Robert R Luedtke; Yogesh Mishra; Qi Wang; Suzy A Griffin; Cathy Bell-Horner; Michelle Taylor; Suwanna Vangveravong; Glenn H Dillon; Ren-Qi Huang; David E Reichert; Robert H Mach
Journal:  ACS Chem Neurosci       Date:  2012-10-12       Impact factor: 4.418

3.  Characterization of [(3) H]LS-3-134, a novel arylamide phenylpiperazine D3 dopamine receptor selective radioligand.

Authors:  Claudia Rangel-Barajas; Maninder Malik; Michelle Taylor; Kim A Neve; Robert H Mach; Robert R Luedtke
Journal:  J Neurochem       Date:  2014-08-19       Impact factor: 5.372

Review 4.  Selectivity of probes for PET imaging of dopamine D3 receptors.

Authors:  Robert K Doot; Jacob G Dubroff; Kyle J Labban; Robert H Mach
Journal:  Neurosci Lett       Date:  2018-03-05       Impact factor: 3.046

5.  Highly Selective Dopamine D3 Receptor Antagonists with Arylated Diazaspiro Alkane Cores.

Authors:  Sean W Reilly; Suzy Griffin; Michelle Taylor; Kristoffer Sahlholm; Chi-Chang Weng; Kuiying Xu; Daniel A Jacome; Robert R Luedtke; Robert H Mach
Journal:  J Med Chem       Date:  2017-11-21       Impact factor: 7.446

6.  In Silico Studies Targeting G-protein Coupled Receptors for Drug Research Against Parkinson's Disease.

Authors:  Agostinho Lemos; Rita Melo; Antonio Jose Preto; Jose Guilherme Almeida; Irina Sousa Moreira; Maria Natalia Dias Soeiro Cordeiro
Journal:  Curr Neuropharmacol       Date:  2018       Impact factor: 7.363

7.  Synthesis and in vitro pharmacological evaluation of indolyl carboxylic amide analogues as D3 dopamine receptor selective ligands.

Authors:  Zhude Tu; Shihong Li; Aixiao Li; Michelle Taylor; David Ho; Maninder Malik; Robert R Luedtke; Robert H Mach
Journal:  Medchemcomm       Date:  2013-09       Impact factor: 3.597

Review 8.  Beyond small-molecule SAR: using the dopamine D3 receptor crystal structure to guide drug design.

Authors:  Thomas M Keck; Caitlin Burzynski; Lei Shi; Amy Hauck Newman
Journal:  Adv Pharmacol       Date:  2014

9.  Evaluation of N-phenyl homopiperazine analogs as potential dopamine D3 receptor selective ligands.

Authors:  Aixiao Li; Yogesh Mishra; Maninder Malik; Qi Wang; Shihong Li; Michelle Taylor; David E Reichert; Robert R Luedtke; Robert H Mach
Journal:  Bioorg Med Chem       Date:  2013-04-06       Impact factor: 3.641

10.  Phenylpiperazine derivatives with selectivity for dopamine D3 receptors modulate cocaine self-administration in rats.

Authors:  T H C Cheung; B C Nolan; L R Hammerslag; S M Weber; J P Durbin; N A Peartree; R H Mach; R R Luedtke; J L Neisewander
Journal:  Neuropharmacology       Date:  2012-08-31       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.